News

Procurement: Better Internet for Kids (BIK) Platform – EU Coordination

Published on | 4 months ago

Programmes Deployment: Best use of technologies

The European Commission (DG CONNECT) has launched the following procurement procedure: 

Better Internet for Kids (BIK) Platform – EU Coordination (EC-CNECT/LUX/2024/OP/0097)

The EU-funded Better Internet for Kids portal (at https://better-internet-for-kids.europa.eu) and the associated coordination tasks are the main subject of this call for tender. The BIK portal will cater to the needs of a community of Safer Internet Centres and support them in the delivery of online safety services aimed at children. This EU hub for child online safety is a key tool to support the European Commission in the implementation of  the European strategy for a better internet for kids (‘Better Internet for Kids’, ‘BIK+ strategy’) (COM (2022)212) at national, European and international level.

Estimated value excluding VAT: €4,000,000

More information can be found on the Funding & Tenders Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1546 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.